Core Insights - DexCom, Inc. has appointed Rick Osterloh to its Board of Directors, effective February 26, 2026, enhancing its leadership team with a seasoned technology executive [1][2]. Company Overview - DexCom is a leader in glucose biosensing technology, having pioneered advancements in this field for over 25 years, significantly transforming diabetes management and glucose tracking for users [6]. Leadership Appointment - Rick Osterloh brings over 20 years of experience in consumer hardware and product operations, currently serving as Senior Vice President at Google, where he oversees a unified group that includes Android, Google Play, Chrome, and various consumer devices [2][4]. - Osterloh's expertise includes innovation oversight, strategic transactions, and long-term planning, which aligns with DexCom's vision for product development [2][3]. Strategic Vision - The appointment of Osterloh is seen as a strategic move to leverage his insights into creating impactful products that integrate innovative technologies, which is crucial for advancing DexCom's mission to improve metabolic health globally [3][4].

Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index increasing by 1.10%. Within the Russell 1000 Growth Index, healthcare, communication services, and financials were the top-performing sectors, while utilities, real estate, and materials lagged. The U.S. economy show ...

Many pharmaceutical companies are looking to develop and market the now highly popular GLP-1 drugs, which help treat diabetes, help patients lose weight, and reduce their risk of a range of conditions linked to obesity. The drugmakers that lead this market over the next decade could reap substantial financial benefits for themselves and their shareholders. But what if companies outside of the pharmaceutical industry benefit as well? One excellent candidate to do so is DexCom (NASDAQ: DXCM). Let's conside ...

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 from $78 while maintaining an Outperform rating, citing a favorable post-earnings setup following a quarterly beat that exceeded expectations. The previous day, DexCom, Inc. (NASDAQ:DXCM) reported fourth-quarter revenue of $1.26 billion, slightly above the $1.25 billion consensus estimate. Management highli ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom, Inc. (NASDAQ:DXCM) from $99 to $95. The analyst maintained his Buy rating on the stock. DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership Plovanic noted that fourth-quarter results and 2026 outlook met expectations, as the company’s strategy remains unchanged. Management continues to fo ...

It's time for the big three. We've got three stocks, three charts, and three trades. Ben Watson, our senior manager of trading services at Charles Schwab, will take us through the charts today.And here to take us through the trades is Dan Deming, the managing partner at KKM Financial. Great to have you both with us. Dan, let's start with a big picture thought on the market action that we're seeing.You know, a bit of a down day, lot of rotation this week. What are some of your takeaways. >> Yeah, I mean, Mar ...

DexCom, Inc. (NASDAQ:DXCM) has shown a modest gain of 1.16% over the past 30 days, indicating positive investor sentiment.The company's projected growth potential of 22.52% underscores its promising future in the medical device industry.With a Piotroski Score of 8, DexCom demonstrates strong financial health, making it an attractive option for long-term investors.DexCom, Inc. (NASDAQ:DXCM) is a prominent player in the medical device industry, specializing in continuous glucose monitoring (CGM) systems for d ...

Core Insights - DexCom, Inc. (DXCM) reported Q4 2025 adjusted EPS of 68 cents, exceeding the Zacks Consensus Estimate of 65 cents by 4.6%, and up from 45 cents in the prior-year quarter [1] - Full-year adjusted EPS was $2.09, reflecting a 27.4% increase from 2024 [1] - GAAP net income per share for Q4 was also 68 cents, up from 38 cents year-over-year [1][2] Revenue Performance - Total revenues for Q4 grew 13% year-over-year to $1.26 billion, surpassing the Zacks Consensus Estimate by 0.6% [3] - Full-year revenues for 2025 increased by 16% to $4.66 billion [4] - U.S. revenues, accounting for 70.8% of total revenues, rose 11% to $891.5 million, while international revenues improved 18% to $368.1 million [5] Margin and Operating Income - Adjusted gross profit reached $799.8 million, a 20.9% increase from the prior-year quarter, with an adjusted gross margin of 63.5%, up 410 basis points year-over-year [9] - Total adjusted operating income was $331.5 million, up 58.2% from the previous year, with an adjusted operating margin of 26.3%, an increase of 750 basis points [10] Financial Position - As of the end of Q4, the company had cash, cash equivalents, and marketable securities totaling $2 billion, down from $3.32 billion in Q3 2025 [11] - Total assets were reported at $6.34 billion, a decrease from $7.5 billion [11] Future Guidance - For 2026, DexCom expects revenues between $5.16 billion and $5.25 billion, indicating 11-13% growth year-over-year [12] - The company anticipates an adjusted gross margin of approximately 63-64% and an adjusted operating margin of about 22-23% [12] Strategic Developments - The nationwide launch of the G7 15-Day system is expected to enhance customer experience and drive growth [8] - The company is preparing for potential Medicare coverage for type 2 non-insulin users, which could significantly expand its market [19] - The G7 system's improvements in accuracy and reliability are expected to support ongoing adoption and market share growth [15]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

分组1 - DexCom reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and showing an increase from $0.45 per share a year ago, representing an earnings surprise of +4.62% [1] - The company achieved revenues of $1.26 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.64% and up from $1.11 billion year-over-year [2] - DexCom has outperformed the market with a 2.7% increase in shares since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $1.18 billion, and for the current fiscal year, it is $2.47 on revenues of $5.22 billion [7] - The Medical - Instruments industry, to which DexCom belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]